You are here: Industry Insights > Pierre Fabre

News List

South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology prnasia
July 06, 2021
The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights to Pierre Fabre to develop and commercialize a family of human antibodies generated ...
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients prnasia
June 30, 2021
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre announced a strategic partnership in support of patients with resected Stage 2 BRAF-mutant melanoma.
The EspeRare Foundation, Pierre Fabre to Develop XLHED Treatment americanpharmaceuticalreview
January 05, 2021
The EspeRare Foundation and the Pierre Fabre group have entered into a license and development collaboration agreement for the development and commercialization of ER-004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia) ...
Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004 prnasia
December 22, 2020
AGC Biologics announced its partnership with Laboratoire Pierre Fabre to manufacture ER-004 – an intra-amniotic drug that will pioneer the treatment of a rare and debilitating genetic disorder.
Global Respiratory Clinics Market will grow at a CAGR of 20.7% over the forecast period - says Absolute Markets Insights prnasia
December 14, 2020
The EspeRare Foundation and the Pierre Fabre group announced today that they have entered into a license and development collaboration agreement for the development and commercialization of ER-004, a prenatal treatment for XLHED (X-linked Hypohidrotic ...
Creation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodies prnasia
November 23, 2020
The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have announced their plans to form a strategic partnership in the field of immuno-oncology research.
Pierre Fabre Initiates Trial for Monoclonal Antibody Targeting VISTA Checkpoint in Solid Tumors americanpharmaceuticalreview
November 18, 2020
Pierre Fabre announced the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, a monoclonal antibody targeting VISTA, developed by ...
NICE no for Pierre Fabre's Braftovi pharmatimes
September 17, 2020
The National Institute for Health and Care Excellence has published the outcome of an appraisal of Pierre Fabre's Braftovi (encorafinib), turning down NHS funding for the drug as a treatment for some patients with advanced colorectal cancer.
Pierre Fabre gets EC nod for Braftovi plus cetuximab to treat BRAFV600E-mutant mCRC pharmaceutical-business-review
June 08, 2020
Pierre Fabre has secured approval from the European Commission (EC) for Braftovi (encorafenib) plus cetuximab (Erbitux) to treat adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.
EU nod for new metastatic colorectal cancer combination pharmatimes
June 05, 2020
Pierre Fabre's Braftovi (encorafenib) has been approved in Europe for use alongside Erbitux (cetuximab) to treat of adults with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.

Previous page 1 2 Next page